scispace - formally typeset
Search or ask a question
Author

Isabel Matas

Bio: Isabel Matas is an academic researcher from University of Barcelona. The author has contributed to research in topics: Genitourinary system & Randomized controlled trial. The author has an hindex of 1, co-authored 4 publications receiving 1 citations.

Papers
More filters
Journal ArticleDOI
TL;DR: In this paper, a comprehensive literature search was conducted electronically using Embase and PubMed to retrieve studies assessing evidence for the efficacy and safety of vaginal laser therapy for GSM or vulvovaginal atrophy up to June 2021.

13 citations

Journal ArticleDOI
TL;DR: In this paper, the authors evaluated subjective and objective variables to evaluate genitourinary syndrome of menopause (GSM) symptoms and concluded that the subjective variables can be differentiated, and not many of the considered objective outcomes are used in the recent literature assessing GSM.
Abstract: New therapeutic options are being considered to treat genitourinary syndrome of menopause (GSM), such as vaginal laser, ospemifene, or prasterone, but there is no explicit agreement in the scientific community for its use. Some concerns have arisen on how to evaluate the improvement of GSM symptoms. In 2003, the FDA suggested possible end points for this purpose: change in severity of symptoms, change in vaginal pH, and change in vaginal maturation index (VMI). Contrarily, the most common assessment tools used to quantify severity and improvement of GSM nowadays are the visual analog scale of GSM symptoms, the vaginal health index, and the female sexual function index. In our opinion, subjective and objective variables to evaluate GSM can be differentiated, and not many of the considered objective outcomes are used in the recent literature assessing GSM. There is the possibility that some therapies present only subjective improvement, giving place to a possible placebo effect that is not being evaluated. To conclude, there is a demand to evaluate whether vaginal pH and VMI are enough to assess objectively GSM changes or new objective approaches should be audited.

5 citations

Journal ArticleDOI
TL;DR: In this article, a randomized controlled trial was conducted at 7 maternity units across Spain to determine whether using an algorithm based on the maternal levels of placental growth factor in women with late preterm preeclampsia to evaluate the best time for delivery reduced the progression to preeclampia with severe features without increasing the adverse perinatal outcomes.

5 citations

Journal ArticleDOI
TL;DR: In this article, the authors evaluated the accuracy of transvaginal ultrasound (TVS) in diagnosing deep endometriosis (DE) involving the uterosacral ligaments (USLs), torus uterinus (TU) or posterior vaginal fornix (PVF) in women with suspected endometria scheduled for laparoscopic surgery.
Abstract: OBJECTIVE To evaluate the accuracy of transvaginal ultrasound (TVS) in diagnosing deep endometriosis (DE) involving the uterosacral ligaments (USLs), torus uterinus (TU) or posterior vaginal fornix (PVF) in women with suspected endometriosis scheduled for laparoscopic surgery. METHODS In this prospective study, consecutive women with clinically suspected pelvic endometriosis who were scheduled for laparoscopic surgery were invited to participate. TVS was performed before surgery. TVS findings were compared with those obtained at laparoscopy and confirmed histologically. The accuracy of TVS for diagnosing DE involving the USLs, TU or PVF was assessed. Additionally, the association of DE involving the USLs, TU or PVF on TVS with symptoms and with DE affecting other pelvic locations was assessed. RESULTS In total, 172 patients were included. The global sensitivity and specificity of TVS in diagnosing DE affecting the USLs, TU and/or PVF were 92% and 87%, respectively. For DE involving the USLs, the accuracy, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio and negative likelihood ratio of TVS were 89.5%, 96.6%, 82.1%, 85.0%, 95.8%, 5.41 and 0.04, respectively; the respective values for DE involving the TU were 86.6%, 83.9%, 89.4%, 89.0%, 84.4%, 7.92 and 0.18, and the respective values for DE involving the PVF were 93.6%, 87.0%, 94.6%, 71.4%, 97.9%, 16.20 and 0.14. Logistic regression analysis showed a significant association between DE affecting the USLs, TU and/or PVF and DE affecting the rectosigmoid (odds ratio, 5.43; P < 0.001). Dyschezia was associated strongly with DE involving the USLs, TU and PVF, while dysmenorrhea was associated significantly with DE involving the TU. CONCLUSION TVS has high accuracy, sensitivity, specificity, PPV and NPV for the detection of DE involving the USLs, TU and PVF in women with suspected endometriosis scheduled for laparoscopic surgery. © 2021 International Society of Ultrasound in Obstetrics and Gynecology.

3 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: The sFlt-1/PlGF ratio has a very high negative predictive value in ruling out the development of preeclampsia within 7 days among women with suspected preeclampia as discussed by the authors .

26 citations

Journal ArticleDOI
TL;DR: Current available menopausal hormonal therapies and novel pharmaceutical alternatives to manage menopausal symptoms are discussed, with menopausal hormone therapy (MHT), including tibolone, remains the most effective treatment for menopausal Symptoms.

23 citations

Journal ArticleDOI
TL;DR: The European Menopause and Andropause Society (EMAS) developed a care pathway for monitoring and guidance of women at midlife, focusing on those approaching the end of the reproductive life-cycle, going through the menopausal transition and beyond as mentioned in this paper .

21 citations

Journal ArticleDOI
TL;DR: In this article , a longitudinal profile of placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1), and the PlGF/sFelt-1 ratio throughout gestation is described to determine whether the association between abnormal biomarker profiles and obstetrical syndromes is strengthened by information derived from placental examination.

15 citations

Journal ArticleDOI
TL;DR: In this paper , a randomized clinical trial with 84 participants in two parallel study groups, both groups received a first-line therapy based on non-hormonal moisturizers and vaginal vibrator stimulation, and participants were randomized to receive 5 weekly sessions of fractional carbon dioxide laser therapy or sham laser therapy.
Abstract: Key Points Question Is vaginal laser treatment safe and effective for genitourinary syndrome of menopause in survivors of breast cancer receiving aromatase inhibitors? Findings In this randomized clinical trial with 84 participants in 2 parallel study groups, both groups received a first-line therapy based on nonhormonal moisturizers and vaginal vibrator stimulation, and participants were randomized to receive 5 weekly sessions of fractional carbon dioxide laser therapy or sham laser therapy. No differences were observed between groups in safety or efficacy outcomes at the 6-month follow-up. Meaning These findings suggest that although vaginal laser treatment was safe, it was not more effective than first-line therapy with placebo treatment in survivors of breast cancer receiving aromatase inhibitors.

9 citations